{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:36:00Z","timestamp":1740893760363,"version":"3.38.0"},"reference-count":48,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T00:00:00Z","timestamp":1323993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2012,3]]},"abstract":"<jats:p> Discoveries of the mechanisms that underlie the pathogenesis of multiple sclerosis have been acquired at an impressive rate over the last few decades and, as a consequence, a growing number of treatments are becoming available for this disease. This review first analyzes the experience from the early stages of the disease-modifying therapies, then, expanding on the concept of early treatment for improved outcomes, it focuses on natalizumab and its major complication, progressive multifocal leukoencephalopathy. We offer views on the risks associated with the use of natalizumab by underscoring the importance of the JC virus serology and by providing preliminary data on our experience with the extended interval dosing of natalizumab. This approach, which advocates individualized treatment plans, raises the question of the minimum effective natalizumab dose. Extended interval dosing suggests efficacy can be maintained while providing advantages of costs and convenience over regular monthly dosing. More data examining this strategy are necessary. <\/jats:p>","DOI":"10.1177\/1756285611431289","type":"journal-article","created":{"date-parts":[[2011,12,17]],"date-time":"2011-12-17T01:35:10Z","timestamp":1324085710000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["From injection therapies to natalizumab: views on the treatment of multiple sclerosis"],"prefix":"10.1177","volume":"5","author":[{"given":"Roberto","family":"Bomprezzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darin T.","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazan J.","family":"Alderazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot M.","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,12,16]]},"reference":[{"key":"bibr1-1756285611431289","first-page":"P07.200","author":"Alderazi Y.J.","year":"2011","journal-title":"Am Acad Neurol Abstract"},{"key":"bibr2-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182050388"},{"key":"bibr3-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e14b7"},{"key":"bibr4-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c97ed3"},{"key":"bibr5-1756285611431289","unstructured":"Biogen Idec (2011) Medical information website, https:\/\/medinfo.biogenidec.com\/"},{"key":"bibr6-1756285611431289","first-page":"214","volume":"13","author":"Birnbaum G.","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"key":"bibr7-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016664"},{"key":"bibr8-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000257109.61671.06"},{"key":"bibr9-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31818f3d6f"},{"key":"bibr10-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-008-1007-3"},{"key":"bibr11-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08430-1"},{"key":"bibr12-1756285611431289","unstructured":"EU Clinical Trials Register (2011) A randomized, blinded, parallel-group, phase 2 study exploring the safety, tolerability and efficacy of multiple regimens of natalizumab in adult subjects with relapsing multiple sclerosis. EudraCT Number: 2010-024000-10; Sponsor Protocol number: 101MS206, https:\/\/www.clinicaltrialsregister.eu"},{"key":"bibr13-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm329"},{"key":"bibr14-1756285611431289","first-page":"S51.004","author":"Foley J.","year":"2011","journal-title":"Am Acad Neurol Abstract"},{"key":"bibr15-1756285611431289","unstructured":"Fox R.J, Kappos L., Cree B., Kaufman M., Jeffrey D., Weinstock-Guttman B. (2011) Effects of a 24-week natalizumab treatment interruption on clinical and radiological parameters of multiple sclerosis disease activity: the RESTORE study. In ECTRIMS, abstract 150."},{"key":"bibr16-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2011.01.003"},{"key":"bibr17-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31818f3d8b"},{"key":"bibr18-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128"},{"key":"bibr19-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431301"},{"key":"bibr20-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70149-1"},{"key":"bibr21-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70237-6"},{"key":"bibr22-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(09)70008-5"},{"key":"bibr23-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"bibr24-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000200778.65597.ae"},{"key":"bibr25-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"bibr26-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70200-X"},{"key":"bibr27-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000260064.77700.fd"},{"key":"bibr28-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181cec45c"},{"key":"bibr29-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70226-1"},{"key":"bibr30-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e7c8a"},{"key":"bibr31-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000335764.14513.1a"},{"key":"bibr32-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d8b1d"},{"key":"bibr33-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000034080.43681.DA"},{"key":"bibr34-1756285611431289","first-page":"P01.194","author":"Pawate S.","year":"2011","journal-title":"Am Acad Neurol Abstract"},{"key":"bibr35-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"bibr36-1756285611431289","doi-asserted-by":"crossref","unstructured":"Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d. Ann Neurol 58: 840\u2013846.","DOI":"10.1002\/ana.20703"},{"key":"bibr37-1756285611431289","first-page":"P03.248","author":"Sandrock A.","year":"2011","journal-title":"Am Acad Neurol Abstract"},{"key":"bibr38-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0344-z"},{"key":"bibr39-1756285611431289","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868010-00005"},{"key":"bibr40-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.073247"},{"key":"bibr41-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70176-X"},{"key":"bibr42-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e55e7"},{"key":"bibr43-1756285611431289","first-page":"5","volume":"14","author":"Tintor\u00e9 M.","year":"2007","journal-title":"Intern MS J"},{"key":"bibr44-1756285611431289","unstructured":"US National Institute of Health (2011) Clinical trials website, http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01067521?term=GALA&rank=1"},{"key":"bibr45-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265393.03231.e5"},{"key":"bibr46-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507085759"},{"key":"bibr47-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.161"},{"key":"bibr48-1756285611431289","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22163"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756285611431289","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756285611431289","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756285611431289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:26:49Z","timestamp":1740821209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756285611431289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,16]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["10.1177\/1756285611431289"],"URL":"https:\/\/doi.org\/10.1177\/1756285611431289","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"type":"print","value":"1756-2864"},{"type":"electronic","value":"1756-2864"}],"subject":[],"published":{"date-parts":[[2011,12,16]]}}}